-
Delta variants are in vogue, but could this variant be more deadly?
Time of Update: 2021-09-05
According to the cohort data published by Professor Abu-Raddad on the preprint server medRxiv, among patients with similar characteristics such as age and gender, compared with the Alpha variant, the possibility of developing a serious disease after being infected with the Beta variant is increased by nearly 25%.
-
Haisco intends to sell the ownership of four related proprietary technologies including DPP1 inhibitors to a Singapore company
Time of Update: 2021-09-05
DPP1 inhibitor project, EZH1/2 dual-target inhibitor project, JAK inhibitor project and Nrf2 agonist project) the proprietary technology ownership in markets outside the Chinese mainland (including Hong Kong, Macao and Taiwan) is transferred to a Singapore company at a transfer price of RMB 52.
-
This top three chief physician was "planted" because of a "black technology"!
Time of Update: 2021-09-05
The staff of the Sichuan Provincial Health Commission found on the "Three Medical Supervision" platform that the data of Feng Moulong, the former chief physician of the Department of Neurosurgery of Sichuan Provincial People's Hospital, was abnormal: a certain type of high-quality consumables he used It accounts for 80% of the total usage in the hospital .
-
New molecular atlas reveals brain cell development trajectory
Time of Update: 2021-09-05
This molecular map can not only help people identify genes related to neurodevelopmental conditions and determine the source of malignant cells in brain cancer, it can also be used as a reference for evaluating brain tissue produced by stem cells in the laboratory, and can improve cells in neurodegenerative diseases.
-
The first domestic CAR-T cell product was recognized as a breakthrough therapeutic product, and the R&D investment exceeded 700 million yuan
Time of Update: 2021-09-05
Source: CDE official websiteOn June 22, Fosun Kate announced that the National Medical Products Administration has formally approved its new drug application for the treatment of human CD19 autologous CAR-T cell therapy product Akirensai injection.
-
More than half of the patients' skin symptoms improved by more than 75%. Eli Lilly's eczema antibody therapy reached the phase 3 clinical endpoint
Time of Update: 2021-09-05
The test results showed that compared with placebo, lebrikizumab improved the skin symptoms of more than half of patients with moderate to severe atopic dermatitis (AD) by at least 75% (EASI 75) .
Reference materials:[1] Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials.
-
Yale Cancer Center team: These strategies are expected to cure non-small cell lung cancer in the next ten years
Time of Update: 2021-09-05
This year, the IMpower 010 study showed that after surgery and chemotherapy in patients with stage II-IIIA NSCLC, adjuvant therapy with PD-L1 inhibitor atezolizumab significantly improved disease-free survival, further supporting the use of checkpoint inhibitors In early NSCLC .
-
Plos Bio reveals: Why has the "fat shield" become a protective umbrella for cancer cells?
Time of Update: 2021-09-05
Cells are the main means of evading the immune system!Related research was published in "Plos Biology" with the title Degranulation enhances presynaptic membrane packing, which protects NK cells from perforin-mediated autolysis .
-
Eli Lilly's Lyumjev U.S. label expands continuous subcutaneous insulin infusion drug delivery via insulin pump
Time of Update: 2021-09-05
Eli Lilly recently announced that the US Food and Drug Administration (FDA) has approved the rapid-acting insulin product Lyumjev® (insulin lispro-aabc injection) 100 units/ml label extension to include: through an insulin pump Continuous subcutaneous insulin infusion (CSII) is administered to improve blood glucose control in adults with type 1 and type 2 diabetes .
-
International Agency for Research on Cancer: The number of cancer patients doubles in the next 50 years, three points are essential for prevention and control
Time of Update: 2021-09-05
The article pointed out that if the current trend is to develop, the annual new cancer cases will reach 34 million by 2070, which is double the data in 2020; and in the comprehensive cancer prevention strategy, the main cancer risk factors, such as smoking and overweight Obesity and high-risk human papillomavirus (HPV) infection will be the top priority for prevention and control .
-
How the key toxic protein of Alzheimer's disease is formed, new research points out the importance of acid-base environment
Time of Update: 2021-09-05
▲Endosomes and lysosomes are the key sites that affect Aβ assembly in cells (picture source: reference [1])The researchers also observed that with the increase of toxic Aβ oligomers, the mislocalization of another protein, tau, appeared in nerve cells, a protein closely related to the progression of Alzheimer's disease .
-
70% of mice eliminate pancreatic cancer!
Time of Update: 2021-09-05
Pancreatic ductal adenocarcinoma (PDAC), often referred to as the "king of cancer", is the most common type of pancreatic cancer and one of the most dangerous cancers in various solid tumors . Chemot
-
Can cervical cancer be eliminated by humans?
Time of Update: 2021-09-05
The study found that in countries where effective cervical cancer screening and HPV vaccination are implemented, the incidence and mortality of cervical cancer remain stable or are declining .
-
What issues should be paid attention to when minors get the new crown vaccine
Time of Update: 2021-09-05
Wang Huaqing said that according to the monitoring and analysis of adverse reactions, the incidence of adverse reactions of children and adolescents vaccinated with the new crown vaccine is not higher than that of adults over 18 years old, including both general reactions and abnormal reactions .
-
Significantly increase the brain volume of children with the latest clinical results of AAV gene therapy
Time of Update: 2021-09-05
Note: The original text has been deletedReference materials:[1] Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy.
Retrieved July 26, 2021, from https:// /news-release/2021/07/26/2268496/0/en/Abeona-Therapeutics-Announces-New-MRI-Data-Showing-Increased-Brain-Volume-in-Young-Patients-with-Sanfilippo-Syndrome-Type -A-MPS-IIIA-After-Treatment-with-ABO-102-Gene-Therapy.
-
Approximately 70% of skin tumors have shrunk significantly
Time of Update: 2021-09-05
On August 12, 2021, Medivir announced that its topical histone deacetylase (HDAC) inhibitor remetinostat has obtained positive results in a phase 2 clinical trial for adjuvant treatment of patients with basal cell carcinoma (BCC) .
Retrieved August 12, 2021, from https:// remetinostat-phase-ii-study-in-basal-cell-carcinoma-published-in-clinical-cancer-research-301354426.
-
After the vaccine has been used, the mask cannot be removed. During the vaccination period, the spread of the virus must be curbed to prevent the emergence of drug-resistant variants.
Time of Update: 2021-09-05
A model study recently published by Natural Science Research’s "Science Report" shows that during the period of large-scale vaccination, non-drug means, such as wearing a mask, are still needed to reduce the spread of the new coronavirus in order to reduce resistance to the vaccine.
-
Early TNBC ushered in the first immunotherapy program Keytruda gains the 30th indication
Time of Update: 2021-09-05
On July 27, 2021, Merck (MSD) announced that the US FDA approved its blockbuster PD-1 antibody therapy Keytruda in combination with chemotherapy, as a neoadjuvant therapy before surgery, and as a single drug as an adjuvant therapy after surgery, to treat high-risk Patients with early triple-negative breast cancer (TNBC) .
-
WuXi Giant Nuo CAR-T Cell Therapy Launched or Delayed
Time of Update: 2021-09-05
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn August 16, WuXi Giant Nuo issued an announcement stating that its targeting CD19 auto-chimeric antigen receptor (CAR) T cell therapy relma-cel injection was used as the third line of relapsed or refractory B-cell lymphoma The new drug marketing application of the therapy is still under review and approval .
-
Research on human gene function is riddled with "shocking" errors
Time of Update: 2021-09-05
In addition, Brian and the research team also screened research papers in the subfield of cancer genetics that had problems before, and found that out of about 600 related papers, more than 25% of the papers contained errors in their nucleotide sequences .
